IT
Islex Therapeutics develops precision therapies targeting beta cell loss in diabetes by utilizing a re-engineered ZnT8 autoantibody to deliver antibody-conjugated therapeutics directly to pancreatic islets. The company is focused on preclinical development of a therapeutic antibody that aims to prevent and reverse autoimmune diabetes while advancing a pipeline of islet-targeted combination therapies.
Updated 3 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Islex Therapeutics develops precision therapies targeting beta cell loss in diabetes by utilizing a re-engineered ZnT8 autoantibody to deliver antibody-conjugated therapeutics directly to pancreatic islets. The company is focused on preclinical development of a therapeutic antibody that aims to prevent and reverse autoimmune diabetes while advancing a pipeline of islet-targeted combination therapies.